

Special Issue

Sickle Cell Anemia: From Genetic Epidemiology to New Therapeutic Strategies

Message from the Guest Editor

Sickle cell anemia is a monogenic disease associated with recurrent painful episodes, inflammation, hemolytic anemia, and progressive multiorgan damage. However, its clinical expression is highly variable and dependent on other genes. The most significant genetic factors are the HbF levels, alpha gene number, and beta-haplotypes. The polymerization of deoxygenated HbS is responsible for red cell sickling, causing impaired blood rheology, intra- and extravascular hemolysis and vaso-occlusion. Hemolytic anemia is associated with cerebral macrovasculopathy, priapism, leg ulcers, and pulmonary hypertension. Blood transfusions remain the mainstay of therapy. Hydroxyurea has been the first drug treatment able to reduce the rate of vaso-occlusive crises and acute chest syndromes. New molecules have emerged, such as crizanlizumab, or voxelotor (GBT-440). However, to date, hematopoietic stem cell transplantation is the only disease-reversing treatment modality and highly successful results obtained with matched-sibling donors support using other donors, such as haplo-identical and unrelated donors, and exploring autologous transplantation modified by gene-therapy.

Guest Editor

Dr. Françoise Bernaudin

Clinical Research, Referral Center for Sickle Cell Disease, CHIC, Creteil Hospital, Creteil, France

Deadline for manuscript submissions

closed (30 January 2020)



Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/24442

Journal of Clinical Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcm@mdpi.com

mdpi.com/journal/

jcm





Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/journal/

[jcm](https://mdpi.com/journal/jcm)



About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67081
Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, The University of
Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.5 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).